Inclusion Criteria:

          -  Must voluntarily sign an informed consent document (ICF)

          -  Morphologically confirmed diagnosis of MDS (inclusive of MDS/MPN) or AML in accordance
             with World Health Organization (WHO) diagnostic criteria

          -  Phase Ib: Subjects may have

               -  Relapsed/refractory AML or MDS or

               -  Treatment naive AML

          -  Phase II Expansion: Subjects may have

               -  Relapsed/refractory AML or MDS or

               -  Treatment naive AML or

               -  Treatment naive MDS

          -  For patients with MDS, must have a Revised International Prognostics Scoring System
             (IPSS-R) risk category of intermediate, high, or very high

          -  Confirmed IDH1 R132 mutation

          -  A bone marrow biopsy must be performed and tissue collected for entrance to the trial

          -  Subjects must have an Eastern Cooperative Oncology Group (ECOG) performance status of
             0-2

          -  Life expectancy of at least 3 months in the assessment of the investigator

          -  Recovery from the non-hematologic toxic effects of prior treatment to grade =< 1, or
             baseline value according to National Cancer Institute (NCI) Common Terminology
             Criteria for Adverse Events (CTCAE) version (v)4.03 classification (excluding
             infertility, alopecia, or grade 1 neuropathy)

          -  Must have adequate hepatic and renal function as demonstrated by the following:

        ALT (SGPT) and/or AST (SGOT) ≤ 3x upper limit of normal (ULN); Direct bilirubin ≤ 1.5 x
        ULN(or ≤ 2x ULN if due to Gilbert's disease); Serum creatinine of 1.5 x ULN or creatinine
        clearance of > 50 mL/min (whichever is lower)

          -  Baseline Fridericia's correction formula (QTcF) =< 450 msec (average of the QTcF
             values of screening triplicate electrocardiography [ECG]swith approximately two-minute
             intervals ) except for those patients with a bundle branch block (BBB)

          -  For fertile men and women, agreement to use effective contraceptive methods for the
             duration of study participation and 90 days after the last dose of study medication

        Exclusion Criteria:

          -  Treatment naive patients who are suitable for and willing to receive intensive
             induction chemotherapy

          -  Patients with active, uncontrolled infection. Patients with infection under active
             treatment and controlled with antibiotics are eligible

          -  Concurrent condition that in the investigator's opinion would jeopardize compliance
             with the protocol

          -  Known history of human immunodeficiency virus (HIV), or known active hepatitis A, B,
             or C infection (hepatitis B carriers with normal liver function test [LFT]s and
             undetectable viral loads are allowed)

          -  Women who are pregnant or nursing

          -  Organ transplant recipients other than bone marrow transplant

          -  Autologous hematologic stem cell transplant within 3 months of study entry. Allogeneic
             hematologic stem cell transplant within 6 months. Grade II, or greater, active
             graft-versus- host disease

          -  Use of an investigational drug within 21 days or 5 half-lives (whichever is shorter)
             prior to the first dose of FT-2102/ASTX727. For investigational drugs for which 5
             half-lives is less than 21 days, a minimum of 10 days between termination of the
             investigational drug and administration of FT-2102/ASTX727 is required

          -  Any major surgery, chemotherapy, or immunotherapy within the last 21 days (limited
             palliative radiation is allowed >= 2 weeks); concurrent hydroxyurea is allowed if less
             than or equal to 2 grams daily

          -  Ongoing immunosuppressive therapy including systemic corticosteroids (prednisone or
             equivalent =< 20 mg daily allowed as clinically warranted). Patients are allowed to
             use topical or inhaled corticosteroids

          -  Concurrent condition that in the investigator's opinion would jeopardize compliance
             with the protocol.

          -  Patients unable to swallow oral medications, or patients with gastrointestinal
             conditions (e.g., malabsorption, resection, etc.) deemed by the Investigator to
             jeopardize intestinal absorption

          -  Patients receiving intrathecal chemotherapy for active central nervous system (CNS)
             disease

          -  Patients who have exhibited allergic reactions to a previously administered IDH1
             inhibitor

          -  Patients with acute promyelocytic leukemia (APL)